Extended indications for anti-tumor necrosis factor-α therapy
نویسندگان
چکیده
منابع مشابه
Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy
Patients receiving anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy are at increased risk for tuberculosis and other granulomatous diseases, but little is known about illness caused by nontuberculous mycobacteria (NTM) in this setting. We reviewed the US Food and Drug Administration MedWatch database for reports of NTM disease in patients receiving anti-TNF-alpha therapy. Of 239 report...
متن کاملAnti-tumor necrosis factor-α agents in noninfectious uveitis.
Anti-tumor necrosis factor-α (anti-TNF-α) agents represent a major breakthrough for the therapeutic management of different autoimmune conditions. Noninfectious uveitis may lead to various sight threatening complications. Hence, from extrapolation of the benefit observed in autoimmune systemic diseases, anti-TNF-α agents are widely used in the treatment of noninfectious uveitis. However, their ...
متن کامل[Anti-tumor necrosis factor-α medications and pregnancy].
En los últimos años se han desarrollado medicamentos que inhiben el TNF-a, porque esta citocina tiene un efecto inflamatorio que condiciona el proceso patológico de diversas enfermedades autoinmunitarias sistémicas, como artritis reumatoide, psoriasis, enfermedades inflamatorias intestinales y otras. Actualmente existen en el mercado farmacéutico 5 fármacos que inhiben el TNF-a: 3 anticuerpos m...
متن کاملAnti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus§
Anti-tumor necrosis factor-alpha induced lupus (ATIL) represents a major diagnostic and therapeutic challenge. Most cases of ATIL are caused by infliximab, followed by etanercept and adalimumab. Symptoms can range from common, mild cutaneous lesions to rare, serious pleural or pericardial effusions, deep venous thrombosis, life-threatening pneumonitis, and neuritis. Constitutional symptoms ofte...
متن کاملMycobacterial diseases developed during anti-tumour necrosis factor-α therapy.
Nontuberculous mycobacterial (NTM) disease and tuberculosis (TB) develop during anti-tumour necrosis factor (TNF)-α therapy. We compared clinical characteristics and outcomes between the two diseases. A total of 1165 patients were screened for TB and treated with TNF-α antagonists from July 2004 to July 2013 for the following conditions: inflammatory bowel disease (n = 422), rheumatoid arthriti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: APLAR Journal of Rheumatology
سال: 2006
ISSN: 0219-4810,1479-8077
DOI: 10.1111/j.1479-8077.2006.00195.x